Fibrocell Science Inc completed a $9.1 million capital raise through preferred stock and warrants. The company also released its second quarter 2012 order information.

Fibrocell received orders for 387 LAVIV™ (azficel-T) biopsies, an increase of 104% from the 189 orders during the first quarter of 2012. During the second quarter of 2012, 85 new physicians placed orders for biopsies, an increase of 60% over first quarter 2012. Also in second quarter of 2012, 39 physicians placed repeat orders for biopsies, an increase of 200% over first quarter 2012. Since the launch of LAVIV in June 2011, Fibrocell has received 706 biopsy orders from 162 physicians.

"We are pleased with the strong demand for LAVIV, which is being driven by reorders and rapid growth in first-time ordering physicians,” says David Pernock, Fibrocell Science Chairman and CEO, in a press release. “July and August are completely booked, and September is nearly 50 percent booked. To meet increasing demand, we have plans for expansion, and we are in discussions with proper regulatory agencies for approval to proceed with our plans."

LAVIV uses a patient’s own fibroblast cells to create a personalized filler. It is the first and only personalized cell therapy approved by the FDA for aesthetic use. For more information about LAVIV, see the Full Prescribing Information at